GeoVax is a clinical-stage biotech developing vaccines and immunotherapies, with no approved products and no commercial revenue. Its lead program, GEO-MVA, is an MVA-based vaccine for mpox and smallpox, targeting a global supply gap left by depleted stockpiles and near-total dependence on a single foreign manufacturer, Bavarian Nordic. GEO-MVA has received an expedited EMA regulatory pathway, allowing GeoVax to proceed directly to a pivotal Phase 3 immunobridging trial planned for the second half of 2026. GeoVax argues GEO-MVA positions it as the first domestic U.S. source of MVA vaccines, aligning with U.S. biodefense and reshoring priorities. Its second program, GEO-CM04S1, is a COVID-19 vaccine targeting immunocompromised patients — such as those with blood cancers or post-transplant — for whom authorized single-antigen vaccines produce inadequate immune responses. GEO-CM04S1 targets both the spike and nucleocapsid proteins, and is currently in Phase 2 trials. A BARDA-funded Phase 2b trial was terminated by the government in early 2025, removing a significant non-dilutive funding source. GeoVax's third program, Gedeptin, is a gene therapy for solid tumors designed to complement immune checkpoint inhibitor therapy, with a Phase 2 trial in head and neck cancer planned for 2027. GeoVax funds operations through equity offerings and intends to commercialize products through government procurement contracts, direct product sales, and international licensing arrangements.